|
515 Companies |
|
302 Products |
|
302 Products |
|
167 Mechanisms of Action |
|
1404 Trials |
|
125634 News |
|
| «12...15451546154715481549155015511552155315541555...15771578» |
- ||| Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
HEOR: YonLife: Patient Directed Intervention to Improve the Quality of Life for Patients With Soft Tissue Sarcoma (clinicaltrials.gov) - Jul 30, 2014
P=N/A, N=77, Not yet recruiting, Sponsor: GWT-TUD GmbH
- ||||| Votrient (pazopanib) / Novartis, BeiGene
New P2 trial, Metastases: Pazopanib vs. Pazopanib Plus Gemcitabine (clinicaltrials.gov) - Jul 30, 2014
P2, N=107, Recruiting, Sponsor: University Medicine Greifswald
- cyclophosphamide / Generic mfg.
Enrollment open, Trial initiation date, Trial primary completion date, Metastases: NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (clinicaltrials.gov) - Jul 30, 2014
P1, N=12, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Not yet recruiting --> Recruiting | Initiation date: Feb 2014 --> Jul 2014 | Trial primary completion date: Jan 2016 --> Jun 2016
- Caprelsa (vandetanib) / Sanofi
Trial primary completion date, Combination therapy: A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas (clinicaltrials.gov) - Jul 29, 2014
P2, N=112, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting | Initiation date: Feb 2014 --> Jul 2014 | Trial primary completion date: Jan 2016 --> Jun 2016 Trial primary completion date: Jul 2014 --> Jul 2016
- | New P2 trial: Evaluation of Technetium Tc 99m Tilmanocept (Lymphoseek®) Localization, Retention, and Distribution in Primary Cutaneous Kaposi's Sarcoma (KS) and Lymphatic Drainage From KS Lesions by SPECT and SPECT/CT Imaging (clinicaltrials.gov) - Jul 28, 2014
P2, N=12, Not yet recruiting, Sponsor: Navidea Biopharmaceuticals
- tasadenoturev (DNX-2401) / DNAtrix
Enrollment change: TARGET-I: DNX-2401 With Interferon Gamma (IFN-?) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors (clinicaltrials.gov) - Jul 28, 2014
P1, N=24, Not yet recruiting, Sponsor: DNAtrix, Inc.
Trial primary completion date: Jul 2014 --> Jul 2016 N=36 --> 24
- | vinorelbine tartrate / Generic mfg.
Trial completion: Vinorelbine in Treating Children With Recurrent or Refractory Cancers (clinicaltrials.gov) - Jul 28, 2014
P2, N=50, Completed, Sponsor: Children's Oncology Group
N=36 --> 24 No longer recruiting --> Completed
- Avastin (bevacizumab) / Roche, rilotumumab (AMG 102) / Amgen
Trial primary completion date: AMG 102 and Avastin for Recurrent Malignant Glioma (clinicaltrials.gov) - Jul 27, 2014
P2, N=36, Recruiting, Sponsor: Katy Peters
No longer recruiting --> Completed Trial primary completion date: Feb 2014 --> Feb 2015
- Biomarker: Identification and Characterization of Molecular Markers in Musculoskeletal Tumors (clinicaltrials.gov) - Jul 25, 2014
P=N/A, N=1000, Recruiting, Sponsor: Balgrist University Hospital
- | ifosfamide / Generic mfg., doxorubicin hydrochloride / Generic mfg., vincristine / Generic mfg.
Trial completion, Surgery, Metastases: Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Children With Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Jul 25, 2014
P2, N=43, Completed, Sponsor: Children's Oncology Group
Trial primary completion date: Feb 2014 --> Feb 2015 Active, not recruiting --> Completed
- Selzentry (maraviroc) / ViiV Healthcare
Trial primary completion date, IO biomarker: Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS) (clinicaltrials.gov) - Jul 24, 2014
P=N/A, N=10, Enrolling by invitation, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed Trial primary completion date: Jun 2013 --> Jan 2015
- | Trial completion, Trial primary completion date: An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation (clinicaltrials.gov) - Jul 24, 2014
P3, N=149, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Trial primary completion date: Jun 2013 --> Jan 2015 Active, not recruiting --> Completed | Trial primary completion date: Aug 2013 --> Jul 2014
- Recentin (cediranib) / AstraZeneca
Trial primary completion date: Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Jul 23, 2014
P2, N=283, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial primary completion date: Aug 2013 --> Jul 2014 Trial primary completion date: Jan 2014 --> Jan 2015
- | tasadenoturev (DNX-2401) / DNAtrix
New P1 trial: TARGET-I: DNX-2401 With Interferon Gamma (IFN-?) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors (clinicaltrials.gov) - Jul 23, 2014
P1, N=36, Not yet recruiting, Sponsor: DNAtrix, Inc.
- Enrollment open: MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors (clinicaltrials.gov) - Jul 23, 2014
P1, N=14, Recruiting, Sponsor: Children's Research Institute
Trial primary completion date: Jan 2014 --> Jan 2015 Not yet recruiting --> Recruiting
- Mozobil (plerixafor) / Sanofi
Enrollment open: Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma (clinicaltrials.gov) - Jul 23, 2014
P1/2, N=29, Recruiting, Sponsor: Stanford University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Enrollment closed: Radiation Therapy to Treat Musculoskeletal Tumors (clinicaltrials.gov) - Jul 23, 2014
P2, N=280, Active, not recruiting, Sponsor: St. Jude Children's Research Hospital
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Trial completion, HEOR: HOPE: Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC) (clinicaltrials.gov) - Jul 23, 2014
P=N/A, N=10, Completed, Sponsor: Comprehensive Cancer Center of Wake Forest University
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- RG4733 / Roche, Erivedge (vismodegib) / Roche
Trial primary completion date, Combination therapy, Metastases: Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Jul 21, 2014
P1b, N=120, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Trial primary completion date: Aug 2014 --> Nov 2014
- Enrollment change: Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program (clinicaltrials.gov) - Jul 21, 2014
P=N/A, N=8000, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Aug 2014 --> Nov 2014 N=5000 --> 8000
- ||| Enrollment change, Trial primary completion date, Metastases: Study of 124I-NM404 in Advanced Solid Malignancies (clinicaltrials.gov) - Jul 21, 2014
P1/2, N=108, Recruiting, Sponsor: University of Wisconsin, Madison
N=5000 --> 8000 N=81 --> 108 | Trial primary completion date: Jul 2014 --> Dec 2014
- Trial primary completion date: Radiation Therapy to Treat Musculoskeletal Tumors (clinicaltrials.gov) - Jul 18, 2014
P2, N=280, Recruiting, Sponsor: St. Jude Children's Research Hospital
N=81 --> 108 | Trial primary completion date: Jul 2014 --> Dec 2014 Trial primary completion date: Jan 2019 --> Jan 2024
- Clinical: Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors (clinicaltrials.gov) - Jul 18, 2014
P=N/A, N=30, Recruiting, Sponsor: University of Iowa
- ||||| Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
New P2 trial: ATREUS - Phase II Study on the Activity of Trabectedin in Patients With Malignant Pleural Mesothelioma (MPM) (clinicaltrials.gov) - Jul 18, 2014
P2, N=79, Recruiting, Sponsor: Mario Negri Institute for Pharmacological Research
- ||| saracatinib (AZD0530) / AstraZeneca
Enrollment closed: A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung (clinicaltrials.gov) - Jul 17, 2014
P2, N=88, Active, not recruiting, Sponsor: Sarcoma Alliance for Research through Collaboration
Trial primary completion date: Jan 2019 --> Jan 2024 Recruiting --> Active, not recruiting
- || Halaven (eribulin mesylate) / Eisai
Trial primary completion date, Metastases: An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma (Study E7389-J081-217) (clinicaltrials.gov) - Jul 17, 2014
P2, N=51, Active, not recruiting, Sponsor: Eisai Co., Ltd.
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2014 --> Jan 2016
- ||||| Kinaction (masitinib) / AB Science
Trial initiation date, Stroma: Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib (clinicaltrials.gov) - Jul 17, 2014
P3, N=210, Ongoing, Sponsor: AB Science
Trial primary completion date: Jan 2014 --> Jan 2016 Initiation date: Apr 2012 --> Apr 2013
- ganetespib (ADX-1612) / Aldeyra, Zaltrap (ziv-aflibercept IV) / Sanofi
New P1 trial, Metastases: Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas (clinicaltrials.gov) - Jul 17, 2014
P1, N=26, Recruiting, Sponsor: National Cancer Institute (NCI)
- | Votrient (pazopanib) / Novartis
Enrollment open, Surgery: ARST1321: Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery (clinicaltrials.gov) - Jul 17, 2014
P2/3, N=340, Recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Apr 2012 --> Apr 2013 Not yet recruiting --> Recruiting
- Vaxira (racotumomab) / Eurofarma, Recombio
Enrollment closed, Trial primary completion date: Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides (clinicaltrials.gov) - Jul 17, 2014
P1, N=15, Active, not recruiting, Sponsor: Laboratorio Elea S.A.C.I.F. y A.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2013 --> Mar 2014
- cixutumumab (IMC A12) / Eli Lilly, Torisel (temsirolimus) / Pfizer
Trial completion, Enrollment change, Metastases: Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma (clinicaltrials.gov) - Jul 17, 2014
P2, N=378, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2013 --> Mar 2014 Active, not recruiting --> Completed | N=174 --> 378
- trebananib (AMG 386) / Amgen, Avastin (bevacizumab) / Roche
Trial primary completion date: Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors (clinicaltrials.gov) - Jul 16, 2014
P2, N=141, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=174 --> 378 Trial primary completion date: Jul 2014 --> Jul 2015
- Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Trial suspension, Metastases: Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer (clinicaltrials.gov) - Jul 16, 2014
P2, N=299, Suspended, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jul 2014 --> Jul 2015 Recruiting --> Suspended
- HEOR: Survivorship Care in Reducing Symptoms in Young Adult Cancer Survivors (clinicaltrials.gov) - Jul 16, 2014
P=N/A, N=455, Not yet recruiting, Sponsor: Fred Hutchinson Cancer Research Center
- | irinotecan / Generic mfg.
New P1 trial, Combination therapy: Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas (clinicaltrials.gov) - Jul 16, 2014
P1, N=53, Not yet recruiting, Sponsor: City of Hope Medical Center
- New P1 trial, Metastases: ?-TEA in Advanced Cancer (clinicaltrials.gov) - Jul 16, 2014
P1, N=62, Recruiting, Sponsor: Providence Health & Services
- Enrollment closed, Trial primary completion date: Proton Beam Therapy for Chondrosarcoma (clinicaltrials.gov) - Jul 16, 2014
P2, N=15, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Suspended Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2015 --> Apr 2016
- Enrollment open: Haploidentical Stem Cell Transplantation and NK Cell Therapy in Patients With High-risk Solid Tumors (clinicaltrials.gov) - Jul 15, 2014
P2, N=12, Recruiting, Sponsor: Samsung Medical Center
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2015 --> Apr 2016 Not yet recruiting --> Recruiting
- Cometriq (cabozantinib capsule) / Exelixis, Ipsen, Takeda, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Trial primary completion date, Metastases: Cabozantinib for Adults With Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Jul 14, 2014
P2, N=50, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2014 --> Sep 2015
- tivantinib (ARQ 197) / Daiichi Sankyo, Kyowa Kirin, Merck (MSD)
Enrollment closed: Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma (clinicaltrials.gov) - Jul 14, 2014
P2, N=49, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2014 --> Sep 2015 Recruiting --> Active, not recruiting
- Trial primary completion date: Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI (clinicaltrials.gov) - Jul 12, 2014
P=N/A, N=20, Recruiting, Sponsor: Stanford University
Recruiting --> Active, not recruiting Trial primary completion date: Mar 2014 --> Mar 2016
- Zokinvy (lonafarnib) / Eiger
Trial primary completion date: Lonafarnib and Temozolomide in Treating Patients With Glioblastoma Multiforme That Is Recurrent or Did Not Respond to Previous Treatment With Temozolomide (clinicaltrials.gov) - Jul 12, 2014
P1, N=35, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Mar 2014 --> Mar 2016 Trial primary completion date: Dec 2014 --> Dec 2015
- imatinib / Generic mfg.
New P1 trial, Stroma: ABILITY: Influence of an Acidic Beverage on the Imatinib Exposure After Major Gastrectomy (clinicaltrials.gov) - Jul 12, 2014
P1, N=12, Not yet recruiting, Sponsor: Radboud University
- | alisertib (MLN8237) / Puma
New P1 trial, Surgery: Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas (clinicaltrials.gov) - Jul 12, 2014
P1, N=24, Not yet recruiting, Sponsor: Thomas Jefferson University
- humanised dinutuximab (Hu14.18K322A) / Essential Pharma
Enrollment open: Pretreatment Anti-Therapeutic Antibodies (PATA) in Patients Treated With hu14.18K322A Antibody (clinicaltrials.gov) - Jul 12, 2014
P=N/A, N=100, Recruiting, Sponsor: St. Jude Children's Research Hospital
Trial primary completion date: Dec 2014 --> Dec 2015 Not yet recruiting --> Recruiting
- erlotinib / Generic mfg.
Enrollment closed: Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma (clinicaltrials.gov) - Jul 12, 2014
P1/2, N=36, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Completed --> Active, not recruiting
- Mozobil (plerixafor) / Sanofi
Trial primary completion date: Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma (clinicaltrials.gov) - Jul 10, 2014
P1/2, N=29, Not yet recruiting, Sponsor: Stanford University
Completed --> Active, not recruiting Trial primary completion date: Nov 2016 --> Jul 2017
- Trial primary completion date, CAR T-Cell Therapy: CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII (clinicaltrials.gov) - Jul 10, 2014
P1/2, N=160, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Nov 2016 --> Jul 2017 Trial primary completion date: Sep 2018 --> Sep 2019
- carboplatin / Generic mfg., paclitaxel / Generic mfg.
Trial primary completion date: Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer (clinicaltrials.gov) - Jul 10, 2014
P=N/A, N=18, Recruiting, Sponsor: Albert Einstein College of Medicine of Yeshiva University
Trial primary completion date: Sep 2018 --> Sep 2019 Trial primary completion date: May 2015 --> Jan 2016
- Mozobil (plerixafor) / Sanofi
Trial initiation date, Trial primary completion date: Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma (clinicaltrials.gov) - Jul 10, 2014
P1/2, N=29, Not yet recruiting, Sponsor: Stanford University
Trial primary completion date: May 2015 --> Jan 2016 Initiation date: Nov 2013 --> Jul 2014 | Trial primary completion date: Nov 2016 --> Jul 2017